Chemical Component Summary

Name2-[2-[2-(1~{H}-benzimidazol-2-yl)ethylamino]ethyl]-~{N}-[(3-fluoranylpyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide
Identifiers2-[2-[2-(1~{H}-benzimidazol-2-yl)ethylamino]ethyl]-~{N}-[(3-fluoranylpyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide
FormulaC21 H21 F N6 O2
Molecular Weight408.429
TypeNON-POLYMER
Isomeric SMILESc1ccc2c(c1)[nH]c(n2)CCNCCc3nc(co3)C(=O)NCc4c(cccn4)F
InChIInChI=1S/C21H21FN6O2/c22-14-4-3-9-24-17(14)12-25-21(29)18-13-30-20(28-18)8-11-23-10-7-19-26-15-5-1-2-6-16(15)27-19/h1-6,9,13,23H,7-8,10-12H2,(H,25,29)(H,26,27)
InChIKeyKNYVRFXIVWUGBZ-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count51
Chiral Atom Count0
Bond Count54
Aromatic Bond Count21

Drug Info: DrugBank

DrugBank IDDB17692 
NameVamifeport
Groups investigational
DescriptionVamifeport is being investigated for the treatment of beta-thalassemia.
Synonyms
  • 2-(2-((2-(1h-benzimidazol-2-yl)ethyl)amino)ethyl)-n-((3-fluoropyridin-2-yl)methyl)-1,3-oxazole-4-carboxamide
  • 4-oxazolecarboxamide, 2-(2-((2-(1h-benzimidazol-2-yl)ethyl)amino)ethyl)-n-((3-fluoro-2-pyridinyl)methyl)-
  • Vamifeport hydrochloride
  • Vamifeport
CategoriesHeterocyclic Compounds, Fused-Ring
CAS number2095668-10-1

Related Resource References

Resource NameReference
PubChem 129052159
ChEMBL CHEMBL4596566